Scholarlink

Background <p>Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Cardiac troponin (cTn) is the cornerstone biomarker for MI diagnosis. This study aims to systematically evaluate research trends, influential contributors, and emerging hotspots in the field exploring the relationship between cTn and MI.</p> Methods <p>Publications on cTn and MI between January 1987 and December 2025 were retrieved from the Web of Science Core Collection. Bibliometric and visualization analyses were performed using VOSviewer, CiteSpace, and the R package “bibliometrix”.</p> Results <p>A total of 5,352 research articles were included, authored by 25,708 researchers from 5,615 institutions in 93 countries/regions. China (1,068 articles), the United States (1,013), and Germany (351) were the most prolific countries. University of Basel led in institutional output, while <i>Clinical Chemistry</i> published the most papers. <i>Circulation</i> ranked highest in both h-index and total citations. Leading authors included Apple FS, Mueller Christian, and Jaffe AS. Keyword co-occurrence analysis identified four principal research clusters: (1) clinical guidelines and disease management, (2) biomarker assays and laboratory methods, (3) diagnosis and risk assessment, and (4) pathophysiology and mechanisms. Temporal and burst keyword analyses revealed a clear evolution: early research focused on traditional cardiac markers and basic mechanisms, while recent years have seen a shift toward high-sensitivity troponin assays, rapid diagnostic algorithms, precision risk stratification, and long-term outcome prediction.</p> Conclusions <p>The field has evolved from foundational studies of myocardial injury mechanisms and biomarker development to clinical translation and, most recently, to precision diagnostics and personalized outcome prediction. Ongoing advances in high-sensitivity troponin assays and data-driven risk models are likely to further enhance early detection, individualized management, and prognostic assessment in MI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationship between cardiac troponin and myocardial infarction: a bibliometric analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Siyuan Yin,
  • Ji Wang,
  • Yiming Shi

摘要

Background

Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Cardiac troponin (cTn) is the cornerstone biomarker for MI diagnosis. This study aims to systematically evaluate research trends, influential contributors, and emerging hotspots in the field exploring the relationship between cTn and MI.

Methods

Publications on cTn and MI between January 1987 and December 2025 were retrieved from the Web of Science Core Collection. Bibliometric and visualization analyses were performed using VOSviewer, CiteSpace, and the R package “bibliometrix”.

Results

A total of 5,352 research articles were included, authored by 25,708 researchers from 5,615 institutions in 93 countries/regions. China (1,068 articles), the United States (1,013), and Germany (351) were the most prolific countries. University of Basel led in institutional output, while Clinical Chemistry published the most papers. Circulation ranked highest in both h-index and total citations. Leading authors included Apple FS, Mueller Christian, and Jaffe AS. Keyword co-occurrence analysis identified four principal research clusters: (1) clinical guidelines and disease management, (2) biomarker assays and laboratory methods, (3) diagnosis and risk assessment, and (4) pathophysiology and mechanisms. Temporal and burst keyword analyses revealed a clear evolution: early research focused on traditional cardiac markers and basic mechanisms, while recent years have seen a shift toward high-sensitivity troponin assays, rapid diagnostic algorithms, precision risk stratification, and long-term outcome prediction.

Conclusions

The field has evolved from foundational studies of myocardial injury mechanisms and biomarker development to clinical translation and, most recently, to precision diagnostics and personalized outcome prediction. Ongoing advances in high-sensitivity troponin assays and data-driven risk models are likely to further enhance early detection, individualized management, and prognostic assessment in MI.